Takeda Pharmaceutical Company Ltd

stated that they own 20.2% of TiGenix – American Depositary Shares (NASDAQ:TIG) in a Schedule 13D disclosure that was filed with the Securities and Exchange Commission (SEC) on Friday, January 12th. The investor owns 56,336,422 shares of the stock worth about $2,329,511,050. The reporting parties listed on the disclosure included Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharma A/S, Takeda A/S and Takeda Europe Holdings BV. The filing is available through EDGAR at this hyperlink.

Separately, EAM Investors LLC purchased a new stake in shares of TiGenix – American Depositary Shares during the second quarter valued at $3,517,000. 5.31% of the stock is owned by institutional investors and hedge funds.

A number of brokerages have recently issued reports on TIG. Zacks Investment Research raised shares of TiGenix – American Depositary Shares from a “hold” rating to a “buy” rating and set a $45.00 target price for the company in a research note on Thursday. Canaccord Genuity lowered shares of TiGenix – American Depositary Shares from a “buy” rating to a “hold” rating and lowered their target price for the company from $50.00 to $42.80 in a research note on Monday. Finally, BidaskClub raised shares of TiGenix – American Depositary Shares from a “strong sell” rating to a “sell” rating in a research note on Wednesday, December 27th.

TiGenix – American Depositary Shares (TIG) traded up $0.34 during trading hours on Friday, reaching $41.35. 16,798 shares of the company were exchanged, compared to its average volume of 26,767. TiGenix – American Depositary Shares has a 52 week low of $14.30 and a 52 week high of $41.69. The company has a quick ratio of 1.36, a current ratio of 1.37 and a debt-to-equity ratio of 0.10.

WARNING: “20.2% Stake of TiGenix – American Depositary Shares (TIG) Maintained by Takeda Pharmaceutical Company Ltd” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/20-2-stake-of-tigenix-american-depositary-shares-tig-maintained-by-takeda-pharmaceutical-company-ltd/1805078.html.

TiGenix – American Depositary Shares Profile

TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases.

Receive News & Ratings for TiGenix - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TiGenix - American Depositary Shares and related companies with Analyst Ratings Network's FREE daily email newsletter.